Tasbeeh Ahmed: Exploring Anticoagulation in Antiphospholipid Syndrome
Tasbeeh Ahmed, Medical Doctor, shared a post on LinkedIn:
“A clot may be the event. APS may be the reason.
Despite the widespread adoption of DOACs, Antiphospholipid Syndrome (APS) remains one of the most important exceptions in modern anticoagulation.
For many patients with thrombotic APS, the choice of anticoagulant is not just a prescription – it can determine the risk of recurrent DVT, stroke, limb ischemia, or pregnancy complications.
- When is Warfarin still the gold standard?
- Why are DOACs discouraged in triple-positive APS?
- What should we do when thrombosis recurs despite therapeutic INR?
- How does management change during pregnancy?
I created this infographic to provide a concise, evidence-based overview of the latest APS anticoagulation recommendations and help clinicians navigate these critical decisions with confidence.
Because in APS, choosing the right anticoagulant can be the difference between preventing the next thrombosis – or missing the opportunity.
What has been your experience managing APS patients in clinical practice?”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn RuksakulpiwatÖ‰ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin